氟伏沙明联合氯硝西泮治疗失独者躯体化障碍的疗效观察
|
摘要
目的:探讨氟伏沙明联合氯硝西泮治疗失独者躯体化障碍的临床疗效。方法:选取2016年6月至2018年5月重庆市精神卫生中心收治的躯体化障碍失独者52例,采用随机数字表法分为观察组和对照组,每组26例。观察组患者给予氟伏沙明联合氯硝西泮治疗,对照组患者单独使用氟伏沙明。采用汉密尔顿抑郁量表(hamilton depression scale,HAMD)、汉密尔顿焦虑量表(hamilton anxiety scale,HAMA)、躯体化症状自评量表(somatic self-rating scale,SSS)及副反应量表(treatment emergent symptom scale,TESS)评估两组患者的临床疗效和不良反应发生情况。结果:治疗1周后,观察组患者的抗焦虑总有效率明显高于对照组,差异有统计学意义(P<0.05)。治疗1、4及8周后,两组患者HAMD评分、HAMA评分、躯体性焦虑因子评分及SSS总分明显低于治疗前;治疗1周后,观察组患者HAMA评分、躯体性焦虑因子评分及SSS总分明显低于对照组,差异均有统计学意义(P<0.05)。观察组、对照组患者的TESS评分分别为(5.1±1.2)、(4.3±1.5)分;不良反应发生率分别为30.8%(8/26)、23.1%(6/26),差异均无统计学意义(P>0.05)。结论:氟伏沙明联合氯硝西泮治疗失独者躯体化障碍的疗效优于单独使用氟伏沙明。
OBJECTIVE: To probe into the clinical efficacy of fluvoxamine combined with clonazepam in treatment of somatization disorder in only-child-lost patients. METHODS: Totally 52 only-child-lost patients with somatization disorder admitted into Chongqing Mental Health Center from Jun. 2016 to May 2018 were extracted to be divided into the observation group and the control group via the random number table, with 26 cases in each. Patients in the observation group were given flvoxamine combined with clonazepam, while the control group received flvoxamine alone. Hamilton Depression Scale(HAMD), Hamilton Anxiety Scale(HAMA), somatic self-rating Scale(SSS) and Treatment Emergent Symptom Scale(TESS) were used to evaluate the clinical efficacy and adverse drug reactions of two groups of patients. RESULTS: After treatment for 1 week, the total effective rate of anti-anxiety of the observation group was significantly higher than that of the control group, and the difference was statistically significant(P<0.05). After treatment for 1, 4 and 8 weeks, HAMD, HAMA, somatic anxiety factor score and SSS total score in two groups were significantly lower than those before treatment; after treatment of 1 week, HAMA score, somatic anxiety factor score and SSS total score in the observation group were significantly lower than those in the control group, with statistically significant differences(P<0.05). The TESS scores of the observation group and the control group were respectively(5.1±1.2) and(4.3±1.5) points, and the incidence of adverse drug reactions were respectively 30.8%(8/26) and 23.1%(6/26), and the difference was not statistically significant(P>0.05). CONCLUSIONS: Fluvoxamine combined with clonazepam was superior to fluvoxamine alone in treatment of somatization disorder in only-child-lost patients.
OBJECTIVE: To probe into the clinical efficacy of fluvoxamine combined with clonazepam in treatment of somatization disorder in only-child-lost patients. METHODS: Totally 52 only-child-lost patients with somatization disorder admitted into Chongqing Mental Health Center from Jun. 2016 to May 2018 were extracted to be divided into the observation group and the control group via the random number table, with 26 cases in each. Patients in the observation group were given flvoxamine combined with clonazepam, while the control group received flvoxamine alone. Hamilton Depression Scale(HAMD), Hamilton Anxiety Scale(HAMA), somatic self-rating Scale(SSS) and Treatment Emergent Symptom Scale(TESS) were used to evaluate the clinical efficacy and adverse drug reactions of two groups of patients. RESULTS: After treatment for 1 week, the total effective rate of anti-anxiety of the observation group was significantly higher than that of the control group, and the difference was statistically significant(P<0.05). After treatment for 1, 4 and 8 weeks, HAMD, HAMA, somatic anxiety factor score and SSS total score in two groups were significantly lower than those before treatment; after treatment of 1 week, HAMA score, somatic anxiety factor score and SSS total score in the observation group were significantly lower than those in the control group, with statistically significant differences(P<0.05). The TESS scores of the observation group and the control group were respectively(5.1±1.2) and(4.3±1.5) points, and the incidence of adverse drug reactions were respectively 30.8%(8/26) and 23.1%(6/26), and the difference was not statistically significant(P>0.05). CONCLUSIONS: Fluvoxamine combined with clonazepam was superior to fluvoxamine alone in treatment of somatization disorder in only-child-lost patients.
引文
[1] 张海芬,谢聪,倪小玲,等.失独家庭的社会支持与主观幸福度及相关影响因素分析[J].神经疾病与精神卫生,2017,17(12):840-843.
[2] 张焕,李新松.中国失独家庭养老服务体系建设研究[J].经济研究导刊,2013(15):102-104.
[3] 石彩红.北京市昌平区计生特殊家庭现状分析及对策建议[J].人口与计划生育,2013(11):26-28.
[4] 汪春运,余琳.审校氟伏沙明在精神科的应用[J].医学研究生学报,2006,19(1):89-91.
[5] 骆艳丽,张明园,吴文源,等.氟西汀治疗持续的躯体形式疼痛障碍的随机双盲安慰剂对照研究[J].临床精神医学杂志,2010,20(1):1-3.
[6] 吴胜,唐丽,罗捷.氟伏沙明与氯米帕明治疗躯体化障碍的随机对照研究[J].四川精神卫生,2015,28(5):417-419.
[7] 颜能,牟艳娟.我国失独家庭心理问题分析及对策研究[J].潍坊工程职业学院学报,2013,26(4):63-65.
[8] Li Y.A perspective on health care for the elderly who lose their only child in China[J].Scand J Public Health,2013,41(6):550-552.
[9] Smith NR,Clark C,Smuk M,et al.The influence of social support on ethnic differences in well-being and depression in adolescents:Findings from the prospective Olympic regeneration in East London(ORiEL)study[J].Soc Psychiatry Psychiatr Epidemiol,2015,50(11):1701-1711.
[10] 姚玉芳,胡波.躯体化障碍的临床特征、治疗及临床转归的研究[J].国际精神病学杂志,2011,38(1):10-14.
[11] 董丽平,赵海宁,陈应柱.躯体化障碍患者的临床特征[J].临床精神医学杂志,2011,21(1):40-42.
[12] 张国林,宋君伟.艾司西酞普兰与文拉法辛治疗躯体形式障碍的对照研究[J].中国健康心理学杂志,2017,25(9):1297-1300.
[13] 秦颖.抗抑郁药在躯体化障碍中的应用[J].天津药学,2011,23(5):60-61.
[14] 韩妍.文拉法辛与帕罗西汀治疗躯体形式障碍的对照分析[J].中国医药指南,2018,16(4):107-108.
[15] 孙涛,傅志俭,孙静,等.氯硝西泮注射液在疼痛治疗中的应用观察[J].中国疼痛医学杂志,2004,10(1):61-62.
[2] 张焕,李新松.中国失独家庭养老服务体系建设研究[J].经济研究导刊,2013(15):102-104.
[3] 石彩红.北京市昌平区计生特殊家庭现状分析及对策建议[J].人口与计划生育,2013(11):26-28.
[4] 汪春运,余琳.审校氟伏沙明在精神科的应用[J].医学研究生学报,2006,19(1):89-91.
[5] 骆艳丽,张明园,吴文源,等.氟西汀治疗持续的躯体形式疼痛障碍的随机双盲安慰剂对照研究[J].临床精神医学杂志,2010,20(1):1-3.
[6] 吴胜,唐丽,罗捷.氟伏沙明与氯米帕明治疗躯体化障碍的随机对照研究[J].四川精神卫生,2015,28(5):417-419.
[7] 颜能,牟艳娟.我国失独家庭心理问题分析及对策研究[J].潍坊工程职业学院学报,2013,26(4):63-65.
[8] Li Y.A perspective on health care for the elderly who lose their only child in China[J].Scand J Public Health,2013,41(6):550-552.
[9] Smith NR,Clark C,Smuk M,et al.The influence of social support on ethnic differences in well-being and depression in adolescents:Findings from the prospective Olympic regeneration in East London(ORiEL)study[J].Soc Psychiatry Psychiatr Epidemiol,2015,50(11):1701-1711.
[10] 姚玉芳,胡波.躯体化障碍的临床特征、治疗及临床转归的研究[J].国际精神病学杂志,2011,38(1):10-14.
[11] 董丽平,赵海宁,陈应柱.躯体化障碍患者的临床特征[J].临床精神医学杂志,2011,21(1):40-42.
[12] 张国林,宋君伟.艾司西酞普兰与文拉法辛治疗躯体形式障碍的对照研究[J].中国健康心理学杂志,2017,25(9):1297-1300.
[13] 秦颖.抗抑郁药在躯体化障碍中的应用[J].天津药学,2011,23(5):60-61.
[14] 韩妍.文拉法辛与帕罗西汀治疗躯体形式障碍的对照分析[J].中国医药指南,2018,16(4):107-108.
[15] 孙涛,傅志俭,孙静,等.氯硝西泮注射液在疼痛治疗中的应用观察[J].中国疼痛医学杂志,2004,10(1):61-62.